# Completeness Review: AIPharmaTrialDesigner

- **Review date:** 2026-07-20
- **Assessment basis:** Source/configuration inspection plus isolated PostgreSQL migration/seed, startup, login, persisted-session, authenticated-API verification, focused tests, and a production frontend build.

## Classification

**Prototype-demo**

## Verdict

This is a clinical/health prototype/demo. Its 130 source files and visible routes/pages demonstrate concepts, but they do not establish durable, integrated, tested execution of the AIPharma Trial Designer workflow.

## Why it is not complete

- 22 project-owned files contain direct provider/chat-completion markers; generic model calls are not a substitute for typed domain tools, grounded evidence, deterministic rules, or evaluations.
- 15 files contain mock, sample, placeholder, simulated, or random-data signals, leaving important outcomes disconnected from authoritative systems.
- No recognizable project-owned automated tests were found for the primary workflow.
- No checked-in CI workflow was found to continuously verify builds, tests, migrations, and security checks.
- No environment example/template was found, leaving required configuration and secret boundaries undocumented.

## Needed features

1. Implement the Pharma Trial Designer care workflow with validated observations, decisions, ownership, follow-up, and clinician-visible uncertainty.
2. Connect authoritative EHR/FHIR, laboratory/imaging, device, pharmacy, scheduling, or payer systems appropriate to the workflow, with consent and failure handling.
3. Validate clinical accuracy, calibration, contraindications, missing-data behavior, bias, and escalation on versioned representative datasets.
4. Require clinician approval, least-privilege access, consent, immutable audit, retention controls, and a clearly documented non-diagnostic boundary.
5. Add contract, integration, authorization, migration, failure-path, and end-to-end tests in CI, plus a documented nondestructive deployment/run path.

## Risks or launch blockers

- Incorrect or unreviewed output can cause patient harm.
- Health data requires strong privacy, access, retention, and audit controls.
- A weak JWT/session-secret fallback can make authentication forgeable when configuration is absent.
- The root launcher can terminate unrelated processes occupying configured ports.
- The root launcher seeds, creates, migrates, or otherwise mutates database state during startup.
- The root launcher installs dependencies at run time, reducing reproducibility and expanding supply-chain risk.

## Evidence inspected

- `backend/package.json` — inspected project-owned structure or implementation evidence.
- `backend/server.js` — inspected project-owned structure or implementation evidence.
- `start.sh` — inspected project-owned structure or implementation evidence.
- `backend/migrations/001_schema.sql` — inspected project-owned structure or implementation evidence.
- `backend/config/database.js` — inspected project-owned structure or implementation evidence.
- `backend/middleware/auth.js` — inspected project-owned structure or implementation evidence.

## Recommended next action

Treat this as a prototype: prove one narrow clinical/health outcome end to end with real data, durable state, domain validation, and tests before expanding its feature catalog.

## Implementation progress

1. Implemented a narrow protocol-design lifecycle with bounded statistical assumptions, protocol/SAP versions, evidence, biostatistical and medical review, IRB approval, conduct, data lock, closure, correction, ownership, and follow-up audit evidence.
2. Partially implemented authoritative clinical integrations: durable consented provider/standard delivery records capture idempotency, retry, receipt, failure, and reconciliation, while existing integration stubs remain fail closed. Real sponsor/EHR/FHIR/lab/imaging/pharmacy systems and credentials remain gates.
3. Partially implemented clinical/statistical validation: durable versioned runs cover calibration, contraindications, missing data, bias, escalation, and representative scenarios; focused tests cover statistical bounds, clinical blocking, approval, and data lock. Formal validated corpora, statistical sign-off, and regulated evidence remain required.
4. Implemented authenticated tenant scoping, qualified-role transitions aligned with existing sponsor/PI roles, independent IRB/biostatistical approval, immutable audit, mandatory secrets, constrained CORS, disabled-by-default test receiver, and non-diagnostic/non-regulatory flags. Formal IRB/sponsor authority and retention governance remain gates.
5. Implemented 6 focused tests, dependency-free CI, additive migration 006, a non-destructive launcher, explicit migrations, and operations documentation.

## Runtime verification (2026-07-20)

- `start.sh` honored isolated PostgreSQL/API/UI ports `55582/5984/5985`; external runtime configuration retained precedence and test startup ran the API without the stale frontend proxy.
- Disposable migrations and explicitly gated demo seeding completed; login, database-backed `/api/auth/me`, and an authenticated API request passed.
- Trial policy tests passed (6/6), and the React production build compiled successfully.
